AstraZeneca signs strategic partnership with Beijing; invests $2.5bn

The pharmaceutical firm expects its workforce in Beijing to grow to 1,700 employees and is launching a JV with BioKangtai to help make vaccines; there is also investment into AI.

Andrew Tjaardstra

March 25, 2025

UK and Swedish pharmaceutical giant AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic research & development (R&D) centre, according to a March 21 announcement.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Companies
North Asia

#astrazeneca
#beijing
#china
#vaccines